Abstract. DNA mapping techniques are being increasingly applied to familial and acquired disorders affecting growth and development. To understand the potential applications of these techniques, one must first have a good understanding of the components and basic structue of DNA, the genetic code, the basic structure of genes and the roles that various components ofgene structure play in regulating gene expression. Following review of this basic information, a variety of DNA mapping techniques including in situ hybridization, Southern blotting, polymerase chain reaction amplification, DNA sequencing and linkage analysis will be covered. Applications of these techniques can enable mapping of unknown genes by detection of loss of allelic heterozygosity or use of linkage analysis and genetic maps. With increasing ease, mutations such as deletions, expansions, rearrangements and point mutations can be detected in diseases such as congenital adrenal hyperplasia, cystic fibrosis, diabetes insipidus, growth hormone deficiency, fragile X syndrome, Laron dwarfism and Turner syndrome. From this discussion, a better understanding of methods of gene localization, uses of genetic maps and rapid, convenient methods to detect a variety of molecular derangements causing familial disorders affecting growth and development will be gained.
If the restriction endonuclease is one like EcoRI it will cut DNA leaving the ends of the two strands offset from each other (1) . This overhang of one DNA strand over the other produces "sticky ends". Such "sticky ends" promote pairing with fragments also cut with EcoRI to form recombinant molecules . Other endonucleases, such as Haefil cut the ends off equally producing so called "blunt ends".
Chromosome
Specific Probes An example of the use of restriction endonuclease analysis to detect the presence or absence of an extra chromosome is Turner syndrome. Usually the karyotype shows a 45, X pattern but some subjects have additional chromosomal fragments. The fragments represent, in some cases, an X chromosome with a deletion or alternatively a portion of a Y chromosome. Distinction between these two is important because the presence of Y chromosomal material predisposes to gonadoblastomas. Fig. 2 illustrates the detection of Y chromosomal fragments by restriction analysis. The solid circle represents a Turner syndrome subject. Her chromosomes included a normal X and a fragment (shown above). The fragment is smaller than either an X or a Y (compare to her father's Y at far right). A DNA probe containing a Y chromosome sequence was used to examine restriction fragments from a control female, the subject's mother, the subject, and the subject's father (2-3). DNA isolated from peripheral blood was digested with EcoRI. The resulting DNA fragments are separated by electrophoresis in agarose gels, the large DNA fragments were located at the top of the gel and the small fragments at the bottom. The DNA fragments are transferred or blotted from the agarose gel to a filter membrane as described by Southern and the filter-bound DNA is then hybridized to a solution containing a Y chromosome probe (32P-radiolabeled single-stranded DNA or RNA copy of sequences specific to the Y Fig. 2 . Analysis of chromosomes and DNA from a Turner syndrome subject. A portion of the 45X+ frag karyotype of the subject (solid circle) is shown above. DNA analysis using a Y chromosome specific probe detects Y-specific sequences in DNA from the patient and her father as shown below (3).
chromosome). The probe molecules anneal to their complementary sequences on the filter to form double-stranded DNA. One strand of these molecules is from the subject's DNA while the other strand is the radiolabeled probe. After hybridization, the filter is washed to remove excess probe and subjected to autoradiography.
The DNA fragments that annealed to the probe appear as bands on the developed film. By comparing the location of these bands with that of markers of known molecular weight, the size of hybridizing DNA fragments is determined. In Fig. 2 Restriction analysis of the structural gene for GH (GH1) is complicated by the fact that it is one of the five GH related genes (5' -GH1: CSHP1:CSH1:GH2:CSH2-3') contained in the GH gene cluster. Although these various genes share extensive sequence homology, only the GH1 locus encodes GH. The CSHP1 gene is of unknown function and encodes a chorionic somatomammotropin hormone (CSH)-like peptide, whereas CHS1 and CSH2 encode CSH, and GH2 encodes a variant GH of unknown function whose gene contains an internal BamHI site. The GH1 gene is flanked by consistent BamHI sites that are 3.8 kb apart. While the CSHP1, CSH1, GH2, and CSH2 genes are sufficiently homologous to hybridize to the GH1 probe, they all are contained in BamHI derived fragments that differ in size from that of GH1. Autoradiograms of DNAs from IGHD 1A subjects lack the 3.8 kb fragments that normally contain the GH1 genes (Fig. 3) . In addition, the intensity of the 3.8 kb bands in DNA from the heterozygous parents is intermediate between that of controls and their affected children. These results show that IGHD 1A subjects are homozygous and their parents are heterozygous for GH1 gene deletions. Since these deletions preclude production of any GH, affected individuals tend to be immunologically intolerant to exogenous GH.
Point Mutations
The detection of certain insulin gene mutations is an example of the detection of point mutations by restriction analysis. Several such mutant insulins have been reported. The clinical features seen in heterozygotes include hyperglycemia with high insulin levels, in the absence of insulin antagonists or receptor antibodies, and a normal response to exogenous insulin. The mutant insulin first described has an 88% decrease in biological potency (6-8). This mutant insulin was foun to have a leucine substituted for phenylalanine at residue 25 in its B chain and is called (LeuB25 insulin) (9). DNA analysis of the LeuB25 insulin gene revealed a nucleotide substitution at position 402. Interestingly , the restriction enzyme Mbo II which cleaves the of Endocrine Disorders normal insulin gene at this point is unable to cleave LeeB25 insulin because of its nucleotide hange. Thus, DNA from a control yield fragments of 336 and 555 by when hybridized to an insulin gene probe. An individual heterozygous for LeuB25 insulin will have a 891 bpy fragment (not seen in controls) because Mbo II cannot cut at the site that separates the 336 and 555 by fragments (10-11). A second mutant insulin (SeeB24 insulin) has a serine for phenylalanine substitution. This mutation can also be detected because it prevents cleavage by Mbo II (12).
Linkage Analysis
Studies of familial diabetes insipidus are an example of mapping the gene responsible for an endocrine disorder by linkage analysis. Linkage analysis is usually done using restriction fragment length polymorphisms (RFLPs) (Fig. 4) . RFLPs result from DNA polymorphisms or base differences that normally occur without any clinical consequences about 1 in every 200 to 500 nucleotides not encoding proteins (13). These differences are usually single nucleotide substitutions some of which can affect a restriction site. A second or insertion/deletion type of DNA polymorphism also called variable numbers of tandem repeats or dinucleotide repeats can alter the DNA fragment size without affecting the enzyme recog- nition site. Finally the presence or absence of a pseudogene (a nonfunctional gene whose sequence is homologous to a functional gene) changes the length of the DNA fragment that is bounded by two restriction sites (14).
In an autosomal dominant form of diabetes insipidus due to arginine vasopressin deficiency (ADNDI) we could not detect deletions, insertions or rearrangements of an arginine vaspopressin (AVP) allele (15). Using an XbaI RFLP closely linked to AVP we found apparent cosegregation with ADNDI in two families (Fig. 5) . The overall LOD score of 2 .70 indicates that the genetic locus for ADNDI maps within or near the AVP locus and suggests that a defective AVP allele may cause this form of diabetes insipidus.
B. Polymerase
Chain Reaction The Polymerase chain reaction (PCR) technology is an important new tool for DNA diagnosis (Fig. 6) (16) (17) (18) . This procedure enables the gene selected for study to be enzymatically amplified relative to the remainder of the genomic DNA. This amplification can yield 107-108 copies of the original segment which can allow direct visualization of the fragments under study thereby precluding the need for Southern blots and radiolabeled probes. PCR amplification makes it possible to amplify specific sequences directly from complex genomic samples without cloning. This ability has led to the development of many new techniques of gene analysis and has revolutionized the way in which inherited disorders are studied. Mutant alleles can be PCR amplified and then rapidly characterized using a combination of segregation analysis, gene scanning, direct DNA sequencing, and RNA transcript analysis (16) (17) (18) .
An example of the utility of PCR amplification is detection of Y chromosome frag- Fig. 7 . Polyacrylamide gel analysis of PCR products of DNA from a family similar to that shown in Fig.  1 DNA molecules that is radioactive with a common 5' end, but of varying length because of the incorporation of a specific 3' end. Next, each of the four reaction products are subjected to electrophoresis and autoradiography and sequence deduction are performed.
Comparison of the mutant and wild-type sequence allows deduction of the mutation. Sequencing not only identifies the mutation but can enable derivation of short oligonucleotide sequences that can be used as probes to detect the presence of that specific mutation in genomic DNA samples from other individuals.
Status of Molecular Endocrinology
For a variety of endocrine disorders including diabetes insipidus, GH deficiency, diabetes mellitus, and vitamin D resistant rickets there are varying amounts of data from DNA studies. I will briefly summarize selected aspects of these data and their conclusions.
A. Diabetes Insipidus (DI) Molecular studies have clarified the basis of genetic forms of DI. These have clarified the structure of the AVP gene (Fig. 9) and assigned it to chromosome 20 (20). Recently, a number of mutations causing autosomal dominant DI have been identified (Fig. 10) (21-24) . The AVP gene (AVP-NP II) contains AVP in exon 1 and its carrier protein (neurophysin or NP II) in exons 1-3. Cosegregation of the ADNDI phenotype and DNA polymorphisms closely linked to the AVP gene was found in two unrelated families, suggesting that muta- C. Laron Dwarfism The first examples of GH receptor or GHR mutations reported were deletions of portions of the gene encoding the extracellular domain ( Fig. 12) 
